跳至主要内容
临床试验/NCT00038636
NCT00038636已完成3 期

A Study of Two Different Doses of ABT-378/Ritonavir in HIV-Infected Patients Who Have Taken Protease Inhibitors and Non-Nucleoside Reverse Transcriptase Inhibitors

Abbott7 个研究点 分布在 3 个国家目标入组 36 人开始时间: 2000年9月1日最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
36
试验地点
7
主要终点
Virologic and immunologic activity evaluations include plasma HIV RNA, CD4 and CD8 cell counts

研究概览

简要总结

The purpose of this study is to determine the safety and effectiveness of a high dose of ABT-378/ritonavir

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •HIV positive
  • •Are at least 18 years old
  • •Subject has not been treated for an active AIDS-defining opportunistic infection within 15 days of screening
  • •HIV RNA level > 1000 copies/mL
  • •Previous therapy with at least one protease inhibitor, at least one non-nucleoside reverse transcriptase inhibitor and at least one nucleoside reverse transcriptase inhibitor

排除标准

  • •Subject is pregnant or breast-feeding
  • •Subject has received an investigational drug within 30 days prior to screening
  • •Have a history of pancreatitis
  • •History of intolerance to ritonavir
  • •Abnormal laboratory tests at screening

结局指标

主要结局

Virologic and immunologic activity evaluations include plasma HIV RNA, CD4 and CD8 cell counts

次要结局

未报告次要终点

研究者

发起方
Abbott
申办方类型
Industry

研究点 (7)

Loading locations...

相似试验